Oncology Institute, Inc. Files 8-K with Material Agreements
Ticker: TOIIW · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1799191
| Field | Detail |
|---|---|
| Company | Oncology Institute, Inc. (TOIIW) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
TOI filed an 8-K detailing material agreements, equity sales, and changes to shareholder rights.
AI Summary
On March 24, 2025, Oncology Institute, Inc. (TOI) entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity securities and material modifications to the rights of security holders. This filing also includes amendments to its articles of incorporation or bylaws and a change in its fiscal year.
Why It Matters
This 8-K filing indicates significant corporate actions by Oncology Institute, Inc., including new agreements and potential changes to shareholder rights, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce complexities and potential risks for investors.
Key Numbers
- 0.0001 — Par Value (Par value of TOI's Common Stock)
- 11.50 — Exercise Price (Exercise price for redeemable warrants)
Key Players & Entities
- Oncology Institute, Inc. (company) — Filer of the 8-K
- 0001799191 (company) — Central Index Key for Oncology Institute, Inc.
- DFP HEALTHCARE ACQUISITIONS CORP. (company) — Former company name of Oncology Institute, Inc.
- 11.50 (dollar_amount) — Exercise price for redeemable warrants
FAQ
What is the nature of the Material Definitive Agreement entered into by Oncology Institute, Inc. on March 24, 2025?
The filing indicates the entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the provided text.
What type of equity securities were sold unregistered by Oncology Institute, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type of securities is not detailed in the provided text.
What specific modifications were made to the rights of security holders?
The filing states there were material modifications to the rights of security holders, but the exact nature of these modifications is not specified in the provided text.
When did Oncology Institute, Inc. change its fiscal year end?
The filing indicates a change in fiscal year, but the specific date or new fiscal year end is not detailed in the provided text.
What was the former name of Oncology Institute, Inc. and when did the name change occur?
The former name of Oncology Institute, Inc. was DFP HEALTHCARE ACQUISITIONS CORP., and the date of the name change was January 8, 2020.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding Oncology Institute, Inc. (TOIIW).